FILE PHOTO: Picture illustration of a vial labelled with the Pfizer-BioNTech coronavirus disease vaccineNEW YORK -The Pfizer/BioNTech COVID-19 vaccine showed 90.7% efficacy against the coronavirus in a clinical trial of children 5 to 11 years old, the U.S. drugmaker said on Friday.
Pfizer's clinical trial in those 5 to 11 years old was not primarily designed to measure efficacy against the virus. Instead, it compared the amount of neutralizing antibodies induced by the vaccine in the children to the response of older recipients in their adult trial. Outside advisors to the FDA are scheduled to meet on Tuesday to vote on whether to recommend that the agency authorize the vaccine for that age group. The FDA's staff is expected to publish their review of the evidence submitted by Pfizer later on Friday.
The second cohort of children have been observed for a shorter time. All of them had received their second dose and more than 70% were more than two weeks post dose two.
Being cancer-stricken and begging CPF Board to repay overdue debt; that which in any case cannot be done as the money had been commingled and funneled to private entity Temasek Holdings for Ho Ching to wager on unviable, untenable and ultimately, invariably doomed gambles
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: TODAYonline - 🏆 1. / 99 Read more »
Source: ChannelNewsAsia - 🏆 6. / 66 Read more »